ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Equities
IPA
CA45257F2008
Pharmaceuticals
Sales 2024 * | 24.59M 17.92M | Sales 2025 * | 29.82M 21.74M | Capitalization | 44.05M 32.11M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.75M | Net income 2025 * | -9M -6.56M | EV / Sales 2024 * | 1.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.48 x |
P/E ratio 2024 * |
-3.48
x | P/E ratio 2025 * |
-4.71
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on ImmunoPrecise Antibodies Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.16% | 29.36B | |
+57.67% | 24.49B | |
-13.89% | 17.31B | |
-18.03% | 11.62B | |
-13.96% | 11.31B | |
-44.23% | 11.26B | |
+7.49% | 8.31B |